p53 alterations and their relationship to SDHD mutations in parasympathetic paragangliomas

Modern Pathology

Volumn 16, Issue 9, 2003, Pages 849-856

  Van Nederveen, Francien H ^a   Dannenberg, Hilde ^a   Sleddens, Hein F B M ^a   De Krijger, Ronald R ^a   Dinjens, Winand N M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Immunohistochemistry; MDM2; p53; Paraganglioma; PCR SSCP

Indexed keywords

MITOCHONDRIAL ENZYME; PROTEIN MDM2; PROTEIN P53; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; SUCCINATE DEHYDROGENASE C; SUCCINATE DEHYDROGENASE D; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FAMILIAL CANCER; FEMALE; GENE; GENE IDENTIFICATION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SDHB; GENE SDHC; GENE SDHD; GENETIC TRANSDUCTION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; PARAGANGLIOMA; PARAGANGLION; PARASYMPATHETIC PARAGANGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADULT; AUTONOMIC NERVOUS SYSTEM DISEASES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; NUCLEAR PROTEINS; PARAGANGLIOMA; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SUCCINATE DEHYDROGENASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0141519103     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000084111.03922.4D     Document Type: Article

References (55)

1. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer 2002;94:730-7.
2. Grufferman S, Gillman MW, Pasternak LR, Peterson CL, Young WG. Familial carotid body tumors: case report and epidemiologic review. Cancer 1980;46:2116-22.
3. Hodge KM, Byers RM, Peters LJ. Paragangliomas of the head and neck. Arch Otolaryngol Head Neck Surg 1988;114:872-7.
4. van Baars F, Cremers C, van den Broek P, Geerts S, Veldman J. Genetic aspects of nonchromaffin paraganglioma. Hum Genet 1982;60:305-9.
5. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 2002;39:178-83.
6. Dannenberg H, Dinjens WN, Abbou M, et al. Frequent germline succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin Cancer Res 2002;8:2061-6.
7. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
8. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49-54.
9. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000;26:268-70.
10. Jensen JC, Choyke PL, Rosenfeld M, et al. A report of familial carotid body tumors and multiple extra-adrenal pheochromocytomas. J Urol 1991;145:1040-2.
11. Pritchett JW. Familial concurrence of carotid body tumor and pheochromocytoma. Cancer 1982;49:2578-9.
12. DeAngelis LM, Kelleher MB, Post KD, Fetell MR. Multiple paragangliomas in neurofibromatosis: a new neuroendocrine neoplasia. Neurology 1987;37:129-33.
13. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 1999;74:543-52.
14. Dannenberg H, de Krijger RR, Zhao J, et al. Differential loss of chromosome 11q in familial and sporadic parasympathetic paragangliomas detected by comparative genomic hybridization. Am J Pathol 2001;158:1937-42.
15. Barnes L, Taylor SR. Vagal paragangliomas: a clinical, pathological, and DNA assessment. Clin Otolaryngol 1991;16:376-82.
16. Sauter ER, Hollier LH, Bolton JS, Ochsner JL, Sardi A. Prognostic value of DNA flow cytometry in paragangliomas of the carotid body. J Surg Oncol 1991;46:151-3.
17. van der Mey AG, Cornelisse CJ, Hermans J, Terpstra JL, Schmidt PH, Fleuren GJ. DNA flow cytometry of hereditary and sporadic paragangliomas (glomus tumours). Br J Cancer 1991;63:298-302.
18. Wang DG, Barros D'Sa AA, Johnston CF, Buchanan KD. Oncogene expression in carotid body tumors. Cancer 1996;77:2581-7.
19. Jyung RW, LeClair EE, Bernat RA, et al. Expression of angiogenic growth factors in paragangliomas. Laryngoscope 2000;110:161-7.
20. Li SL, Goko H, Xu ZD, et al. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998;291:469-79.
21. Wang DG, Johnston CF, Barros D'Sa AA, Buchanan KD. Expression of apoptosis-suppressing gene bcl-2 in human carotid body tumours. J Pathol 1997;183:218-21.
22. Hirawake H, Taniwaki M, Tamura A, Amino H, Tomitsuka E, Kita K. Characterization of the human SDHD gene encoding the small subunit of cytochrome b (cybS) in mitochondrial succinate-ubiquinone oxidoreductase. Biochim Biophys Acta 1999;1412:295-300.
23. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001;69:1186-97.
24. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002;87:4771-4.
25. Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Hum Pathol 1973;4:251-63.
26. Pacheco-Ojeda L, Durango E, Rodriquez C, Vivar N. Carotid body tumors at high altitudes: Quito, Ecuador, 1987. World J Surg 1988;12:856-60.
27. Chedid A, Jao W. Hereditary tumors of the carotid bodies and chronic obstructive pulmonary disease. Cancer 1974;33:1635-41.
28. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
30. Deb SP. Function and dysfunction of the human oncoprotein MDM2. Front Biosci 2002;7:d235-43.
31. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
33. Lam KY, Lo CY, Wat NM, Luk JM, Lam KS. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 2001;54:443-8.
34. Welkoborsky HJ, Gosepath J, Jacob R, Mann WJ, Amedee RG. Biologic characteristics of paragangliomas of the nasal cavity and paranasal sinuses. Am J Rhinol 2000;14:419-26.
35. Cheng L, Leibovich BC, Cheville JC, et al. Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer 2000;88:844-52.
36. van der Sijp JR, van Meerbeeck JP, Maat AP, et al. Determination of the molecular relationship between multiple tumors within one patient is of clinical importance. J Clin Oncol 2002;20:1105-14.
37. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
38. Elkablawy MA, Maxwell P, Williamson K, Anderson N, Hamilton PW. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol 2001;194:436-43.
39. McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995;71:981-5.
40. Koumenis C, Alarcon R, Hammond E, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001;21:1297-310.
41. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000;20:3224-33.
42. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
43. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
44. Battifora H. p53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-37.
45. Devilee P, van Schothorst EM, Bardoel AF, et al. Allelotype of head and neck paragangliomas: allelic imbalance is confined to the long arm of chromosome 11, the site of the predisposing locus PGL. Genes Chromosomes Cancer 1994;11:71-8.
46. Lianes P, Orlow I, Zhang ZF, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
47. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995;85:1608-14.
48. Riou G, Barrois M, Prost S, Terrier MJ, Theodore C, Levine AJ. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol Carcinog 1995;12:124-31.
49. Pruneri G, Pignataro L, Carboni N, et al. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Mod Pathol 1997;10:785-92.
50. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999;12:580-6.
51. Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol 1998;72:6348-55.
52. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.
53. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
54. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
55. Guran S, Tali ET. p53 and p16INK4A mutations during the progression of glomus tumor. Pathol Oncol Res 1999;5:41-5.